Investing in Anti-Aging Stocks
Heart disease runs in my family.
My grandfather had a heart attack in his 50s.
My uncle had a massive heart attack when he was in his 40s.
And my father, who hasn’t had a heart attack, has had an angioplasty and has been on heart medication for years.
Knowing that it runs in my family, I’m pretty vigilant about getting checked out every year by my doctor. Regular exercise and clean eating have probably done a lot to lessen my chances of having serious heart conditions, too.
But when it comes to our genetic codes, our destinies are somewhat predetermined.
No matter how much I exercise and how clean I eat, I’m still at risk for heart disease because my DNA and RNA have far more to do with my destiny than what I eat or how many pushups I can do.
But this could soon change.
The End of Heart Disease
Doctors from biotech firm Verve Therapeutics have developed a new gene-editing serum that switches off the genes that regulate both LDL cholesterol and triglycerides.
Essentially, it’s a single gene-editing injection given to young people so they can live a life without heart disease –– even if their genetic code would make them more susceptible to heart disease.
It’s a gene-hack that, if proven successful, could eliminate the risk of heart disease forever.
Given that heart disease affects 48% of the total U.S. adult population, this is a very big deal.
But, it’s also just the tip of the iceberg when it comes to how people will battle disease in the very near future.
The End of Aging
It may seem hard to imagine now, but it won’t be long until doctors will be able to not only edit out disease from our genetic code but also significantly slow the aging process.
Imagine for a moment being able to live longer and not having to deal with all the illnesses and diseases that come with aging.
This is not science fiction. This is real research that’s showing real results right now. And it’s all based on a new class of anti-aging drugs called senolytics.
I’ll tell you more about senolytics in a moment, but first, it’s important to understand how people age.
You see, throughout one’s life, cells divide until they encounter some form of biologic stress, at which point they pull a form of cellular emergency brake causing them to cease dividing forever.
The result is an accumulation of senescent cells that secrete large quantities of harmful proteins, which cause inflammation, tissue degradation, and the production of growth factors that alter the tissue microenvironment, which is believed to lead to age-associated diseases.
This is where senolytics come into play, by eliminating accumulated senescent cells that facilitate aging and drive many of the common age-associated diseases we deal with today. Some of these include cardiovascular disease, Type 2 diabetes, hypertension, hearing loss, and osteoporosis.
This is huge!
Well, according to the Longevity Fund, a venture capital firm that invests specifically in anti-aging related companies, a single age-related indication could be worth a couple hundred billion dollars.
For the full effect, here’s what that looks like: $200,000,000,000.00
That’s roughly the GDP of Portugal.
From a single age-related indication!
My friends, don’t think for a second that I’m not getting a piece of this action.
And you should, too.
But which anti-aging company is best in the breed?
Well, I just follow the money.
One anti-aging company I’m particularly bullish on is the same one that raised more than $150 million from guys like Jeff Bezos and Peter Thiel, two of the richest people on the planet. Bezos has a net worth of $161 billion, and Thiel has a net worth of $2.3 billion.
These guys didn’t get this rich by betting on the wrong horses. And if they’re in big on this one anti-aging company, so am I.
That’s why I put together this short research report which not only highlights this company but also illustrates why guys like Bezos and Thiel have ponied up millions to get a piece of it.
The report is free, and you can download it here.
To a new way of life and a new generation of wealth...
@JeffSiegel on Twitter
Jeff is the founder and managing editor of Green Chip Stocks, a private investment community that capitalizes on opportunities in alternative energy, organic food markets, legal cannabis, and socially responsible investing. He has been a featured guest on Fox, CNBC, and Bloomberg Asia, and is the author of the best-selling book, Investing in Renewable Energy: Making Money on Green Chip Stocks. For more on Jeff, go to his editor's page.
Energy Demand will Increase 58% Over the Next 25 Years
After getting your report, you’ll begin receiving the Energy and Capital e-Letter, delivered to your inbox daily.